Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index

Introduction: Portal hypertension is one of the main clinical complications of chronic liver diseases. In only 30% of cirrhotic patients who take propranolol, the hepatic venous pressure reduces to under 12 mm/Hg. The results of studies on the efficiency of losartan (an angiotensin II receptor antag...

Full description

Bibliographic Details
Main Authors: Mahtab Bayani, Ladan Fakhriyehasl, Seyed kazem Nezam, Baktash Bayani
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2021-04-01
Series:Patient Safety and Quality Improvement Journal
Subjects:
Online Access:https://psj.mums.ac.ir/article_18370_cdb589df57598c427551e8350a6f5a8e.pdf
id doaj-fe812e055e374d13a2c69fa903781a76
record_format Article
spelling doaj-fe812e055e374d13a2c69fa903781a762021-08-31T07:42:57ZengMashhad University of Medical SciencesPatient Safety and Quality Improvement Journal2345-44822345-44902021-04-0192919710.22038/psj.2021.55640.131218370Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive IndexMahtab Bayani0Ladan Fakhriyehasl1Seyed kazem Nezam2Baktash Bayani3Department of Internal Diseases, Mehr Hospital, Mashhad, Iran.Department of Radiology, Zahedan University of Medical Sciences, Zahedan, Iran.Assistant Professor of Gastroenterology and Hepatology, Zahedan Medical University, Zahedan, Iran.Department of Heart Disease, Mehr Hospital, Mashhad, Iran.Introduction: Portal hypertension is one of the main clinical complications of chronic liver diseases. In only 30% of cirrhotic patients who take propranolol, the hepatic venous pressure reduces to under 12 mm/Hg. The results of studies on the efficiency of losartan (an angiotensin II receptor antagonist) in reducing portal hypertension have been controversial so far. Hepatic venous pressure gradient (HVPG) is measured using an invasive method of catheterization. Studies have shown that the measurement of the renal resistive index (RI) by Doppler ultrasonography has a direct relationship with HVPG. The study population included cirrhotic patients who referred to Ali-ibn-Abi Talbe Clinic, Zahedan, Iran. This clinical trial was conducted based on a self-controlled method. Materials and Methods: In total, 30 cirrhotic patients who met the inclusion criteria were selected for the study.  The patients were treated with propranolol 10 mg twice a day for one month, and losartan was then added to their medication regimen. The renal RI of patients was measured before and after losartan administration. Results: The mean of renal RI of patients treated with both propranolol and losartan (0.659±0.58) was higher than that of the patients treated with only propranolol (0.635±0.597) (P=0.005). Conclusion: Our results showed that cirrhotic patients who received propranolol had high renal RI before and after receiving losartan. Accordingly, it seems that losartan had no effects on reducing HVPG hypertension in patients taking propranolol.https://psj.mums.ac.ir/article_18370_cdb589df57598c427551e8350a6f5a8e.pdfdoppler ultrasonographyhepatic venous pressure gradientlosartanportal hypertensionrenal resistive index
collection DOAJ
language English
format Article
sources DOAJ
author Mahtab Bayani
Ladan Fakhriyehasl
Seyed kazem Nezam
Baktash Bayani
spellingShingle Mahtab Bayani
Ladan Fakhriyehasl
Seyed kazem Nezam
Baktash Bayani
Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
Patient Safety and Quality Improvement Journal
doppler ultrasonography
hepatic venous pressure gradient
losartan
portal hypertension
renal resistive index
author_facet Mahtab Bayani
Ladan Fakhriyehasl
Seyed kazem Nezam
Baktash Bayani
author_sort Mahtab Bayani
title Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
title_short Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
title_full Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
title_fullStr Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
title_full_unstemmed Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index
title_sort evaluation of the difference between cirrhotic patients receiving propranolol and those receiving propranolol plus losartan in terms of renal artery resistive index
publisher Mashhad University of Medical Sciences
series Patient Safety and Quality Improvement Journal
issn 2345-4482
2345-4490
publishDate 2021-04-01
description Introduction: Portal hypertension is one of the main clinical complications of chronic liver diseases. In only 30% of cirrhotic patients who take propranolol, the hepatic venous pressure reduces to under 12 mm/Hg. The results of studies on the efficiency of losartan (an angiotensin II receptor antagonist) in reducing portal hypertension have been controversial so far. Hepatic venous pressure gradient (HVPG) is measured using an invasive method of catheterization. Studies have shown that the measurement of the renal resistive index (RI) by Doppler ultrasonography has a direct relationship with HVPG. The study population included cirrhotic patients who referred to Ali-ibn-Abi Talbe Clinic, Zahedan, Iran. This clinical trial was conducted based on a self-controlled method. Materials and Methods: In total, 30 cirrhotic patients who met the inclusion criteria were selected for the study.  The patients were treated with propranolol 10 mg twice a day for one month, and losartan was then added to their medication regimen. The renal RI of patients was measured before and after losartan administration. Results: The mean of renal RI of patients treated with both propranolol and losartan (0.659±0.58) was higher than that of the patients treated with only propranolol (0.635±0.597) (P=0.005). Conclusion: Our results showed that cirrhotic patients who received propranolol had high renal RI before and after receiving losartan. Accordingly, it seems that losartan had no effects on reducing HVPG hypertension in patients taking propranolol.
topic doppler ultrasonography
hepatic venous pressure gradient
losartan
portal hypertension
renal resistive index
url https://psj.mums.ac.ir/article_18370_cdb589df57598c427551e8350a6f5a8e.pdf
work_keys_str_mv AT mahtabbayani evaluationofthedifferencebetweencirrhoticpatientsreceivingpropranololandthosereceivingpropranololpluslosartanintermsofrenalarteryresistiveindex
AT ladanfakhriyehasl evaluationofthedifferencebetweencirrhoticpatientsreceivingpropranololandthosereceivingpropranololpluslosartanintermsofrenalarteryresistiveindex
AT seyedkazemnezam evaluationofthedifferencebetweencirrhoticpatientsreceivingpropranololandthosereceivingpropranololpluslosartanintermsofrenalarteryresistiveindex
AT baktashbayani evaluationofthedifferencebetweencirrhoticpatientsreceivingpropranololandthosereceivingpropranololpluslosartanintermsofrenalarteryresistiveindex
_version_ 1721184017394434048